286 related articles for article (PubMed ID: 24916483)
1. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.
Klein DJ; Foster D; Schorr CA; Kazempour K; Walker PM; Dellinger RP
Trials; 2014 Jun; 15():218. PubMed ID: 24916483
[TBL] [Abstract][Full Text] [Related]
2. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial.
Klein DJ; Foster D; Walker PM; Bagshaw SM; Mekonnen H; Antonelli M
Intensive Care Med; 2018 Dec; 44(12):2205-2212. PubMed ID: 30470853
[TBL] [Abstract][Full Text] [Related]
3. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
Dellinger RP; Bagshaw SM; Antonelli M; Foster DM; Klein DJ; Marshall JC; Palevsky PM; Weisberg LS; Schorr CA; Trzeciak S; Walker PM;
JAMA; 2018 Oct; 320(14):1455-1463. PubMed ID: 30304428
[TBL] [Abstract][Full Text] [Related]
4. Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis.
Chang T; Tu YK; Lee CT; Chao A; Huang CH; Wang MJ; Yeh YC
Crit Care Med; 2017 Aug; 45(8):e858-e864. PubMed ID: 28445237
[TBL] [Abstract][Full Text] [Related]
5. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry.
De Rosa S; Cutuli SL; Ferrer R; Antonelli M; Ronco C;
Artif Organs; 2021 Jun; 45(6):E187-E194. PubMed ID: 33377184
[TBL] [Abstract][Full Text] [Related]
6. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES.
Rachoin JS; Foster D; Dellinger RP
Contrib Nephrol; 2010; 167():111-118. PubMed ID: 20519905
[TBL] [Abstract][Full Text] [Related]
7. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial.
Iba T; Fowler L
J Intensive Care; 2017; 5():40. PubMed ID: 28690852
[TBL] [Abstract][Full Text] [Related]
8. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion.
Nakamura T; Sugaya T; Koide H
Shock; 2009 May; 31(5):454-9. PubMed ID: 18838948
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock.
Shoji H; Opal SM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672437
[TBL] [Abstract][Full Text] [Related]
10. Abdominal Septic Shock - Endotoxin Adsorption Treatment (ASSET) - endotoxin removal in abdominal and urogenital septic shock with the Alteco® LPS Adsorber: study protocol for a double-blinded, randomized placebo-controlled trial.
Lipcsey M; Tenhunen J; Sjölin J; Frithiof R; Bendel S; Flaatten H; Kawati R; Kuitunen A; Tønnessen TI; Rubertsson S
Trials; 2016 Dec; 17(1):587. PubMed ID: 27931259
[TBL] [Abstract][Full Text] [Related]
11. Importance of Endotoxin Clearance in Endotoxemic Septic Shock: An Analysis From the Evaluating Use of PolymyxinB Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemic Septic Shock (EUPHRATES) Trial.
Rachoin JS; Foster D; Giese R; Weisberg LS; Klein DJ
Crit Care Explor; 2020 Feb; 2(2):e0083. PubMed ID: 32211615
[TBL] [Abstract][Full Text] [Related]
12. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.
Cruz DN; Antonelli M; Fumagalli R; Foltran F; Brienza N; Donati A; Malcangi V; Petrini F; Volta G; Bobbio Pallavicini FM; Rottoli F; Giunta F; Ronco C
JAMA; 2009 Jun; 301(23):2445-52. PubMed ID: 19531784
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: a protocol for a systematic review and meta-analysis.
Fujii T; Ganeko R; Kataoka Y; Featherstone R; Bagshaw SM; Furukawa TA
BMJ Open; 2016 Nov; 6(11):e012908. PubMed ID: 27872122
[TBL] [Abstract][Full Text] [Related]
14. Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock.
Mitaka C; Kusaoi M; Kawagoe I; Satoh D
Acute Crit Care; 2021 May; 36(2):85-91. PubMed ID: 33813808
[TBL] [Abstract][Full Text] [Related]
15. Endotoxin removal: bringing the mission to North America.
Foster D; Klein DJ; Guadagni G; Walker PM
Blood Purif; 2014; 37 Suppl 1():14-7. PubMed ID: 24457490
[TBL] [Abstract][Full Text] [Related]
16. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis.
Iwagami M; Yasunaga H; Doi K; Horiguchi H; Fushimi K; Matsubara T; Yahagi N; Noiri E
Crit Care Med; 2014 May; 42(5):1187-93. PubMed ID: 24365858
[TBL] [Abstract][Full Text] [Related]
17. Polymyxin B hemoperfusion: a mechanistic perspective.
Ronco C; Klein DJ
Crit Care; 2014 Jun; 18(3):309. PubMed ID: 25043934
[TBL] [Abstract][Full Text] [Related]
18. Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients.
Lee CT; Tu YK; Yeh YC; Chang T; Shih PY; Chao A; Huang HH; Cheng YJ; Yeh YC;
J Crit Care; 2018 Feb; 43():202-206. PubMed ID: 28915395
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial.
Osawa I; Goto T; Kudo D; Hayakawa M; Yamakawa K; Kushimoto S; Foster DM; Kellum JA; Doi K
Crit Care; 2023 Jun; 27(1):245. PubMed ID: 37344804
[TBL] [Abstract][Full Text] [Related]
20. Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis.
Terayama T; Yamakawa K; Umemura Y; Aihara M; Fujimi S
Surg Infect (Larchmt); 2017 Apr; 18(3):225-233. PubMed ID: 28092497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
